Xilio Therapeutics eyes the fast track to the clinic with $95M in investor cash to test redesigned IL-2, CTLA-4 meds

Nicole DeFeudis

Editor

About three years after joining the search for IL-2 and CTLA-4 therapies without all those nasty side effects, Xilio Therapeutics has teed up $95 million …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Xilio Therapeutics eyes the fast track to the clinic with $95M in investor cash to test redesigned IL-2, CTLA-4 meds

Nicole DeFeudis

Editor

Sign up to read this article for free.

Director Oligonucleotide R&D

Bachem

Bubendorf, BL, Switzerland

Exclusive: Bucking gene-editing downturn, Tune raises $175M to bring epigenetic editing to clinic

Biogen offers to buy out struggling neuro partner Sage Therapeutics

Chasing the next wave of obesity drugs, Metsera files for an IPO

Four biotechs emerge with $800M and in-licensed assets on Friday

Exclusive: Moderna's former top scientist has a new startup using AI to improve mRNA therapies

Updated: CDER Director Patrizia Cavazzoni to step down ahead of Trump presidency

Xilio Ther­a­peu­tics eyes the fast track to the clin­ic with $95M in in­vestor cash to test re­designed IL-2, CT­LA-4 meds

Editor

Sign up to read this article for free.

more like this

Bachem

Bubendorf, BL, Switzerland

Xilio Therapeutics eyes the fast track to the clinic with $95M in investor cash to test redesigned IL-2, CTLA-4 meds